ERBB2 and breast cancer: Tumors of patients diagnosed with advanced BC were at higher grade, higher proliferation rate as determined by Ki67 immunohistochemistry, more often Her2/neu overexpressing, and with less favorable receptor profile, that is, nonluminal-A like subtype (60.2% vs. 27.5%, p < 0.0001) or triple negative cancers.